Background-The enzyme 11␤-hydroxysteroid dehydrogenase (11␤-HSD) prevents inappropriate activation of the nonselective mineralocorticoid receptors by glucocorticoids. Renal activity of 11␤-HSD is decreased in patients with apparent mineralocorticoid excess (SAME), licorice-induced hypertension, and essential hypertension. Although expressed in vascular cells, the role of 11␤-HSD in the regulation of vascular tone remains to be determined. Methods and Results-Glycyrrhizic acid (GA; 50 mg/kg IP, twice daily for 7 days) caused a significant inhibition of 11␤-HSD activity and induced hypertension in Wistar-Kyoto rats (157 versus 127 mm Hg in controls; PϽ0.01). After 11␤-HSD inhibition, aortic endothelial nitric oxide (NO) synthase (eNOS) protein content, nitrate tissue levels, and acetylcholine-induced release of NO were blunted (all PϽ0.05 versus controls). In contrast, vascular prepro-endothelin (ET)-1 gene expression, ET-1 protein levels, and vascular reactivity to ET-1 were enhanced by GA treatment (PϽ0.05 versus controls). Chronic ET A receptor blockade with LU135252 (50 mg · kg Ϫ1 · d Ϫ1 ) normalized blood pressure, ET-1 tissue content, vascular reactivity to ET-1, vascular eNOS protein content, and nitrate tissue levels and improved NO-mediated endothelial function in GA-treated rats (PϽ0.05 to 0.01 versus untreated and verapamil-treated controls).
T he enzyme 11␤-hydroxysteroid dehydrogenase (11␤-HSD) confers mineralocorticoid receptor specificity by metabolizing glucocorticoids to their receptor-inactive 11dehydro derivatives. 1, 2 Impaired renal conversion of cortisol to cortisone results in the congenital syndrome of apparent mineralocorticoid excess (SAME), which results in sodium retention and severe hypertension, 1,3 mediated in part through activation of both mineralocorticoid and glucocorticoid receptors. 4 Moreover, reduced urinary excretion of steroid metabolites, which suggests reduced activity of 11␤-HSD, has been shown in patients with licorice-induced and essential hypertension. 5 Recently, 2 forms of 11␤-HSD have been identified as separate gene products, HSD1 and HSD2, characterized by specific cofactor requirements for NADP and NAD, respectively. 3 In addition to its role in the kidney, 11␤-HSD has also been demonstrated in cardiac fibroblasts, coronary artery vascular smooth muscle, and endothelial cells, 6, 7 where it is thought to function in a paracrine fashion, modulating local glucocorticoid and mineralocorticoid activity, vascular tone, and endothelial function.
In patients with essential hypertension, endothelial dysfunction precedes the rise of blood pressure and predisposes to the development of structural vascular changes. 8, 9 This suggests that changes in 11␤-HSD activity could influence a number of factors involved in these processes. The endothelium releases vasoactive mediators such as nitric oxide (NO) and endothelin-1 (ET-1), both of which are importantly involved in the regulation of vascular tone 10 and structure. 11 Endothelial NO synthase (eNOS) 12 converts L-arginine into NO and L-citrulline, 13 and its expression, as well as the release of NO, is particularly reduced in salt-sensitive hypertension. 14 Because of its potency, prolonged pressor action, 15 stimulatory effects on the sympathetic nervous system, 8 and growth-promoting properties, 16 ET-1 has been implicated in the pathogenesis or maintenance of several forms of sodiumrelated hypertension, and its expression is enhanced in small resistance arteries of patients with moderate to severe hypertension. 17 The production of ET-1 is regulated by endothelium-derived vasoactive substances, components of the coagulation cascade, and growth factors implicated in hypertension-induced vascular changes. 18 ET-1 is produced by vascular endothelial cells, smooth muscle cells, and macrophages and acts through activation of G i proteincoupled ET A and ET B receptors. 10, 19 The first clinical evidence is available demonstrating that ET antagonism effectively lowers blood pressure in patients with mild to moderate hypertension, which suggests that ET receptor blockade may represent a further therapeutic advance in the treatment of patients with cardiovascular disease. 20 Hence, the aim of the present study was to further the understanding of mechanisms leading to the development and maintenance of hypertension and to examine the effects of 11␤-HSD inhibition by glycyrrhizic acid (GA), the active component of licorice, 21 on the regulation of circulating and tissue ET-1, its vascular receptors, and NO in this animal model of human hypertension.
Methods

Animals and Blood Pressure Measurements
Male Wistar-Kyoto rats (mean weight 250 g, 13 weeks old) were obtained from Charles River, Germany. Rats were treated with either saline or GA 50 mg/kg IP twice daily. Rats were treated with GA for 7 days and then assigned to treatment with the orally available selective nonpeptide ET A receptor antagonist LU135252 (50 mg/kg) or verapamil (25 mg/kg) administered with chow for 2 weeks. Animals had free access to water, were maintained at 24°C, and were kept on a 12-hour light/dark cycle. Food and drug intake were monitored during the entire study. Systolic arterial blood pressure was measured in conscious animals by the tail-cuff method. An average of at least 5 independent readings were taken. The study design and experimental protocols were approved by the institutional animal care committee (Kommission für Tierversuche des Kantons Zürich, Switzerland) and were in accordance with American Heart Association guidelines for research animal use.
Index of 11␤-HSD Activity
The urine steroid metabolites THA (11-dehydro-tetrahydrocorticosterone), THB (tetrahydrocorticosterone), and allo-THB (5␣tetrahydrocorticosterone) were extracted, hydrolyzed, derivatized, and analyzed by gas chromatography. Ketone groups were first transformed to methoximes by incubation of samples overnight at room temperature with methoxylamine hydrochloride (2% wt/vol in pyridine). Hydroxyl groups were then silylated with trimethylsilyl imidazole (100 L) for 3 hours at 100°C. Finally, steroids were purified on lipidx minicolumns eluted with a solution containing hexane:hexamethyldisilazane:pyridine (98:1:1); then, they were dried and kept in 300 L of hexane. Steroid analysis was performed on a Hewlett Packard 3398A gas chromato-graph equipped with a DB-1 column. Vector gas was nitrogen, and steroids, eluted according to a temperature gradient (150°C to 280°C), were detected by flame ionization at the exit of the column. Signals were integrated and compared with those of internal standards for quantification. Steroids were identified by comparison of their retention time with that of pure THA, THB, and allo-THB. The ratio of (THB ϩ allo-THB)/THA was used as an index of 11␤-HSD activity, and the difference between groups was evaluated by Student paired t test.
Tissue and Plasma Preparation and Analysis
Rats were euthanized, and the thoracic aorta was removed. Vascular function was assessed as described previously. 22 Drugs were discontinued 24 hours before the vascular studies. ET-1 was determined by specific radioimmunoassay. 23 Measurement of plasma and tissue nitrate was performed as described previously. 24 Prepro-ET-1, ET A receptor, and ET B receptor mRNA were determined by quantitative polymerase chain reaction. 24 eNOS protein levels were determined by Western blot analysis. 24
Calculations and Statistical Analysis
Data are given as meanϮSEM, and n indicates the number of animals. Maximal contraction or relaxation (as percent precontraction in rings precontracted to 70% of contraction induced by potassium chloride 100 mmol/L) and negative logarithm of the concentration causing half-maximal relaxation or contraction (pD 2 value) were determined for each individual dose-response curve by nonlinear regression analysis with MatLab software. For multiple comparisons, results were analyzed with ANOVA followed by Bonferroni correction; for comparison between 2 values, the unpaired Student t test or nonparametric Mann-Whitney test was used when appropriate. 25 A P value Ͻ0.05 was considered significant.
Results
11␤-HSD Activity
(THB ϩ allo-THB)/THA ratio as an index of 11␤-HSD activity was markedly decreased in GA-treated rats (PϽ0.05 versus controls; Figure 1A ).
Body Weight, Systolic Blood Pressure, and Heart Rate
Body, kidney, liver, and heart weight did not differ between groups either before or after GA treatment or during treatment with the ET A receptor antagonist or the calcium channel blocker verapamil. Systolic blood pressure was increased after GA treatment and returned to baseline levels after ET A receptor blockade and verapamil, whereas heart rate was unaltered ( Figure 1B ).
Alterations of the ET System
Prepro-ET-1 and ET Receptor Gene Expression
Quantitative polymerase chain reaction revealed increased (3-fold) prepro-ET-1 gene expression after GA treatment. ET B receptor gene expression was decreased by 50%, whereas ET A receptor gene expression remained unchanged ( Figure 2 ).
ET-1 Plasma and Tissue Concentrations
Plasma concentrations of ET-1 were decreased after GA treatment, whereas vascular ET-1 levels were augmented ( Figure 3 ; PϽ0.05). ET A receptor blockade normalized vascular ET-1 content (Figure 3 ; PϽ0.05 versus controls). Verapamil, however, did not change vascular ET-1 levels ( Figure 3 ; PϭNS versus GA-treated controls).
Increases in ET-1 were specific for aorta, because ET-1 content of renal tissue remained unchanged. Renal cortex ET-1 averaged 1200Ϯ65 and 1300Ϯ50 pg/mg in control and GA-treated groups, respectively; renal medulla ET-1 values were 900Ϯ40 and 850Ϯ37 pg/mg tissue in control and GA-treated rats, respectively.
Vascular Reactivity to ET-1
ET-1-induced concentration-dependent contractions were enhanced after chronic GA treatment and ameliorated by ET A receptor blockade ( Figure 4 ; PϽ0.05 versus GA-treated rats). Vascular reactivity to ET-1 remained unchanged after verapamil treatment (Figure 4 ; PϭNS versus GA-treated controls).
Norepinephrine and Potassium Chloride
Contractions to norepinephrine were unaffected (Table) . Contractile responses to 100 mmol/L KCl did not differ between groups (not shown).
Alterations of the NO System eNOS Protein Levels
Western blot analysis revealed that aortic eNOS protein levels decreased in 11␤-HSD-deficient rats and were normalized after selective ET A blockade ( Figure 5 ).
Nitrate Tissue Concentrations
Aortic tissue nitrate concentrations were reduced by 50% by GA treatment. In contrast to verapamil, ET A receptor blockade restored vascular nitrate concentrations ( Figure 6 ; PϽ0.05 versus GA rats). Renal cortex nitrate levels were slightly decreased compared with controls (from 95Ϯ10 to 70Ϯ7 g/g protein in GA-treated animals), whereas renal medulla nitrate levels were unaltered by GA treatment (98Ϯ11 versus 110Ϯ7 g/g protein).
NO-Mediated Endothelial Function
Endothelium-dependent relaxation of aortic rings to acetylcholine was blunted after GA treatment ( Figure 7) . In contrast to verapamil, ET A blockade ameliorated NO-mediated endothelial function (Figure 7 ). Relaxations to acetylcholine were blocked by N G -nitro-L-arginine methyl ester (L-NAME; Fig-Figure 1 . A, 11␤-HSD activity. (THB ϩ allo-THB)/THA as an index of 11␤-HSD activity was markedly decreased in GA-treated rats. *PϽ0.05 vs control; nϭ3. B, Blood pressure. Systolic blood pressure was increased by 1 week of GA treatment compared with placebo and returned to baseline after treatment with ET A receptor antagonist and with verapamil. Heart rate remained unchanged. *PϽ0.05 vs control; #PϽ0.05 vs GA-treated controls; nϭ7 to 8. ure 7) and were unaffected by superoxide dismutase (not shown). Endothelium-independent relaxations to sodium nitroprusside were comparable in all groups (Table) .
Cultured Human Endothelial Cell ET-1 Production After Treatment With Corticosterone and GA
To further delineate mechanisms, particularly whether ET-1mediated vascular changes after 11␤-HSD inhibition were dependent on changes in blood pressure, the impact of glucocorticoids on ET-1 production was investigated in cultured human EA-hy-926 endothelial cells. ET-1 production did not change during 24 hours of exposure to corticosterone (0.1ϫ10 Ϫ6 mol/L) or GA (5ϫ10 Ϫ6 mol/L; Figure 8 ). In contrast, ET-1 production increased when human EA-hy-926 endothelial cells were treated with both corticosterone and GA in the same concentrations (Figure 8; PϽ0.01 ). This suggests that activation of ET-1 after 11␤-HSD inhibition can occur, at least in part, independently of changes of blood pressure but that such activation is dependent on the presence of glucocorticoids.
Discussion
This study for the first time demonstrates that activation of the vascular ET-1 gene and protein expression mediate the development of hypertension induced by the 11␤-HSD inhibitor GA. In addition, chronic ET A receptor blockade, but not calcium channel blockade, prevents vascular ET-1 upregula-tion and restores vascular eNOS protein, nitrate content, and NO-mediated endothelial function in 11␤-HSD inhibitorinduced hypertension. 11␤-HSD activity, which regulates corticosterone (cortisol in humans) access to its receptors and prevents inappropriate occupancy of type 1 mineralocorticoid receptors by glucocorticoids, is decreased in patients with licorice-induced as well as salt-sensitive hypertension. 5 However, after administration of 11␤-HSD inhibitors, there is a discrepancy between sodium retention (which occurs in the first few days) and blood pressure elevation (which occurs after chronic administration), 26 suggesting that the rise in blood pressure initially may not be dependent on sodium retention. Correspondingly, in dexamethasone hypertension, the glucocorticoid-induced increase in vascular reactivity precedes the rise in blood pressure independent of renal mineralocorticoid receptor activation, 6 which suggests that 11␤-HSD expressed in vascular smooth muscle 6 and endothelial cells 7 may play a role in mediating changes in vascular function. Indeed, we provide here the first evidence that activation of the vascular ET-1 system and impairment of NO formation may contribute to the development of hypertension induced by administration of the 11␤-HSD inhibitor GA. Activation of the ET system has previously been shown in human hypertension, and indirect evidence suggests that increased vascular ET-1 content may be related to hypertensive end-organ damage and remodeling. 27 Indeed, in the present study, increased vascular prepro-ET-1 gene expression and protein levels of mature ET-1 were significantly increased, thus indicating an important role for ETs in 11␤-HSD inhibitor-induced hypertension. Because ETs have a predominant paracrine action and are primarily released abluminally toward the medial layer of the vessel wall, 28 plasma levels represent spillover to the circulation and poorly reflect the activation of local ET-1 in disease states. In the present study, reduced plasma levels were a surprising but consistent finding and are most likely the result of changes in pulmonary and/or hepatic and renal clearance, as demonstrated in one of our recent studies. 29 Most interestingly, increased glucocorticoid activity, as it occurs in this model, upregulates pulmonary ET B receptors, 30 which are responsible for pulmonary clearance of ET-1. This may explain reduced circulating levels of ET-1 in the presence of a marked upregulation of prepro-ET-1 and vascular reactivity to ET-1. Increased vascular ET-1 content and contractions to ET-1 indicate local activation of the ET system after 11␤-HSD inhibition. Tissue content reflects not only rates of ET-1 synthesis but also the level of receptor occupancy and rate of subsequent cellular internalization. Tissue reactivity represents the overall balance between vasoconstrictor responses and the level of activity of counterregulatory vasodilator mechanisms. Hence, the same degree of ET receptor occupancy in the absence of specific counterregulatory vasodilator mechanisms, eg, NO production, would be expected to result in an enhanced vascular reactivity to ET-1. In line with these findings, vasoconstriction to endogenous ET-1 is increased in the peripheral vasculature of patients with essential hypertension. 31 To further determine whether there is a causal relationship between activation of the ET system and hypertension and the associated functional changes, animals were chronically treated with the selective ET A receptor antagonist LU135252, which normalized blood pressure levels and reversed activation of the vascular ET-1 system. Surprisingly, chronic treatment with LU135252 lowered blood pressure and normalized vascular ET-1 levels in the absence of increased ET A receptor gene expression. Similar observations were made previously in the setting of an activated ET system in another model of hypertension. 11 Thus, it is possible that ET A receptors are also involved in the regulation of ET-1 tissue levels in hypertension induced by 11␤-HSD inhibition. The mech-anisms by which ET receptor blockade prevents the increase in vascular ET-1 content in vivo are currently unclear but may involve autocrine, ET A receptor-mediated regulation of ET-1 mRNA and protein, as observed in vascular smooth muscle and cardiac fibroblasts. 32 Although the ET antagonist was discontinued 24 hours before the vascular studies, a time period that is almost twice the half-life of the drug in the body, receptor binding of ET A receptors by LU135252 might theoretically affect vascular reactivity. However, we have previously shown that in normal animals, LU135252 does not change vascular responsiveness to ET in organ chamber experiments, ie, it appears to be eliminated from the tissues under the conditions of the assay. 33 Furthermore, the reduction of ET-1 tissue levels could be related to LU135252mediated restoration of endothelial release of NO, which is a potent inhibitor of ET-1 production. 18 Indeed, vascular eNOS protein and tissue levels of nitrate/nitrite, the breakdown products of NO and endothelium-dependent relaxation to acetylcholine, were markedly reduced. Because relaxations to acetylcholine were completely blocked by L-NAME and unaffected by superoxide dismutase, these data suggest that endothelial release of NO is impaired in GA-induced hypertension. ET B receptors in vascular tissue have previously been linked to NO-mediated vasodilatory responses, which counteract ET A receptor-mediated vasoconstriction. 34 Hence, downregulation of ET B receptors as observed in the present study may contribute to the reduced endothelium-dependent relaxation to acetylcholine and may enhance ET contractions by allowing unopposed action of the peptide at vasoconstrictor ET A receptors. Indeed, in the present study, ET A receptor antagonism normalized vascular eNOS protein expression and nitrate levels. However, several additional mechanisms could conceivably underlie the increased tissue levels and contractile responsiveness to ET-1 in aortas from GA-treated hypertensive rats. Effects may reflect adaptive changes in vascular tissues during hypertension development or even nonspecific sensitizing effects of GA unrelated to 11␤-HSD inhibition. The role of other pressor systems cannot be ruled out but appears unlikely because contractile responses to norepinephrine were unaffected, and the renin-angiotensin system is suppressed in models of mineralocorticoid or . Cultured human endothelial cell ET-1 production after treatment with corticosterone and GA. In cultured human EA-hy-926 endothelial cells, ET-1 production did not change during 24 hours of exposure to corticosterone (0.1ϫ10 Ϫ6 mol/L) or GA (5ϫ10 Ϫ6 mol/L), but did change when treated with both corticosterone and GA at the same concentrations. **PϽ0.01 vs control. nϭ3. glucocorticoid excess. However, because angiotensin II is a potent stimulus of ET-1 formation and some effects of angiotensin II can be blocked by ET antagonists, 27, 33, 35 angiotensin II could contribute to the enhancement of vascular ET-1 in 11␤-HSD inhibitor-induced hypertension.
Maximal Response and Sensitivity (pD 2 ) of Concentration-Dependent Contractions to Norepinephrine and Relaxations to Sodium Nitroprusside in Aortic Rings of Treated Rats
Previous studies 27 have shown that local expression of prepro-ET-1 mRNA and peptide protein increases in vascular tissue only in some forms of hypertension. The ET-1 system is not activated, for example, in chronic NO deficiency in L-NAME-induced hypertension or in spontaneously hypertensive rats. 27 This suggests that hypertension per se is not sufficient to induce vascular ET-1 formation and that a pressure-independent component is also involved. Indeed, calcium channel blockade did not restore blunted NO-mediated endothelial function and did not normalize vascular reactivity and tissue content of ET-1, thus indicating blood pressure-independent effects of ET-1 in 11␤-HSD inhibitor-induced hypertension. This interpretation is further supported by additional in vitro studies conducted on human EA-hy 926 endothelial cells, which demonstrated that neither corticosterone nor GA alone affected ET-1 production. If present together in the incubation medium, however, ET-1 formation approximately doubled. This is consistent with previous reports showing that glucocorticoids per se do not affect ET-1 release from bovine aortic endothelial cells. 36 Indeed, the present study clearly demonstrates that enhanced production of ET-1 in endothelial cells by GA occurs only in the presence of corticosterone and hence is unlikely to reflect incidental actions of GA such as gap junction inhibition. Furthermore, ET-1 stimulation under these conditions occurs independently of increases in blood pressure or systemic changes in electrolyte balance. Hence, hypertension induced by 11␤-HSD inhibition may involve not only glucocorticoid and mineralocorticoid receptor-mediated modulation of renal function but also modulation of the cardiovascular ET-1 and NO systems.
Recent evidence indicates that elevated aldosterone levels play an important role in the development and progression of myocardial fibrosis and hypertrophy in congestive heart failure [37] [38] [39] and that sodium retention is not the primary mechanism of cortisol-induced hypertension. 4 These findings may be particularly relevant to the present study because the current data suggest that reduced activity of 11␤-HSD, owing to the generation of endogenous inhibitors or gene defects, could represent an important additional, aldosterone-independent mechanism through which inappropriate access of glucocorticoids to vascular receptors may influence vascular tone. In line with that, evidence of reduced activity of 11␤-HSD has not only been shown in patients with licorice-induced hypertension but also in patients with essential hypertension. 5 In conclusion, the present study for the first time demonstrates that activation of the vascular ET-1 system mediates the development of hypertension induced by the 11␤-HSD inhibitor GA. Chronic ET A receptor blockade, but not calcium channel blockade with verapamil, prevents vascular ET-1 upregulation and restores NO-mediated endothelial function, thus indicating beneficial effects of ET receptor blockade independent of its blood pressure-lowering effects. Hence, ET antagonism may emerge as a new therapeutic approach in the treatment of cardiovascular disease associated with reduced activity of 11␤-HSD.
